Soul Healthcare (India) Pvt. Ltd.

7th KM Jaspur Road Kashipur-244713 (U.K)

CERTIFICATE OF ANALYSIS

(Under Drugs & Cosmetics Act, 1940 & Rules Made There Under)

Name of Sample	**ALAR** (Cetirizine Dihydrochloride Tablets IP 10 mg)	**A.R. Number**	**SHPT/383/26**
Batch No.	T-260929	**Reference No.**	SFPT/383/26
Batch Size	5,00,000 tablets	**Date of Receiving**	26/10/2026
Date of Mfg.	Sep. 2026	**Date of Completion**	27/10/2026
Date of Exp.	Aug. 2028	**Sample of Quantity**	50 Tabs.
Manufactured By	Soul Healthcare (I) Pvt. Ltd.	**Mfg. Lic. No.**	43/UA/2007
Manufactured for	Dr. Arora Healthcare P. Ltd.	**Ref. to Protocols**	In House Specification

Name of Test	**Specification**	**Result of Analysis**
Description	White, elongated, biconvex, film coated tablet with break line one side.	**Complies**
Identification	Positive for Cetirizine Hydrochloride	**Complies**
Average weight	NLT 138.2 mg to NMT 160.6 mg	**149.47 mg**
Uniformity of weight	NMT two of the individual weight deviates from the average weight by more than the ± 7.5percent and none deviate by more than the ± 15 percent.	**Minimum -7.0%** **Maximium +3.2%**
Disintegration time	Not more than 30 Minutes	**1 Minute**
Dissolution	NLT 80 % of the stated amount of $C_{21}H_{25}ClN_2O_3,2HCl$.	**108.19 %**
Related substances	Single impurity NMT 0.5 % Total Impurity NMT 1.0 %	**Complies**
Uniformity of contents	The tablet comply the individual values obtained is the limit 85 % to 115 % of the average contents.	**With in limit**
Assay	**Each film coated tablet contains**	

Name of Ingredient	**Claim**	**Observed**	**Limit**
Cetirizine Hydrochloride IP	**10 mg**	**10.18 mg**	**NLT 9.0 mg to NMT 11.0 mg**

Opinion : In the opinion of the undersigned, the sample referred to above is **STANDARD QUALITY** with respect to above specification.

	Prepared By	**Checked By**	**Approved By**
Sign. & Date	27/10/2026	Kajal 27/10/2026	27/10/2026